الفهرس 
Introduction and aim of the work
Timing of Androgen Deprivation therapyOnly 14 pages are availabe for public view
 |  | from | 202 |  |  |
| | | from | 202 | | |
Abstract
Prostate cancer is the second most common male malignancy after lung cancer in Europe & North America. The life time risk for American men is now 1 in 6 (16%). It is estimated that 189.000 new cases of prostate cancer were diagnosed in 2002 & approximately 30.200 will die of the disease. The present study included fourty patients with localized & locally advanced prostate cancer with no evidence of distant metastasis. 20 patients received radiotherapy & adjuvant hormonal treatment antiandrogen in the form of cyproterone acetate (androcur) 200300 mg daily (group I), while 20 patients received radiotherapy alone (group II). All patients were treated by conventional radiotherapy using supervoltage linac 610 MV with 2D planning system, phase I 5000 cGy over 5.5 weeks (whole pelvic irradiation) and phase II 2000 cGy over 2 weeks (boost prostate). The period of follow up ranged from 6 to 42 months with a median follow up period 19 months. We found statistically significant increase in overall survival in patients with early stage disease. However, progression free survival was found significantly increased in patients received combined treatment modality & patients with early stage disease. On the other hand, no significant correlation with pretreatment PSA level, gleason score & LN involvement